Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513

Watchlist Manager
Chengdu Easton Biopharmaceuticals Co Ltd Logo
Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513
Watchlist
Price: 30.57 CNY 1.46% Market Closed
Market Cap: 5.4B CNY
Have any thoughts about
Chengdu Easton Biopharmaceuticals Co Ltd?
Write Note

Chengdu Easton Biopharmaceuticals Co Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Chengdu Easton Biopharmaceuticals Co Ltd
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513
Operating Income
ÂĄ204.7m
CAGR 3-Years
3%
CAGR 5-Years
7%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Operating Income
ÂĄ2.6B
CAGR 3-Years
-2%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Operating Income
ÂĄ3.5B
CAGR 3-Years
10%
CAGR 5-Years
20%
CAGR 10-Years
24%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Operating Income
ÂĄ5.8B
CAGR 3-Years
-3%
CAGR 5-Years
3%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Operating Income
ÂĄ4B
CAGR 3-Years
2%
CAGR 5-Years
9%
CAGR 10-Years
1%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Operating Income
-ÂĄ749.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Chengdu Easton Biopharmaceuticals Co Ltd
Glance View

Market Cap
5.4B CNY
Industry
Pharmaceuticals

Chengdu Easton Bio Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of chemical raw materials and chemical drug preparations. The company is headquartered in Chengdu, Sichuan and currently employs 1,188 full-time employees. The company went IPO on 2020-09-02. The firm's main products are chemical generic drugs. Its products include nalmefene hydrochloride injection, caffeine citrate injection, ibuprofen injection, bisoprolol fumarate tablets, ubenimex, etc. Its products are used in the fields of anesthesia and analgesia, cardiovascular, anti-tumor, digestion and children's medicine. The firm operates its businesses within the China market and to overseas markets such as Russia, Switzerland, Tunisia, Germany, South Korea and Japan.

Intrinsic Value
51.06 CNY
Undervaluation 40%
Intrinsic Value
Price

See Also

What is Chengdu Easton Biopharmaceuticals Co Ltd's Operating Income?
Operating Income
204.7m CNY

Based on the financial report for Dec 31, 2023, Chengdu Easton Biopharmaceuticals Co Ltd's Operating Income amounts to 204.7m CNY.

What is Chengdu Easton Biopharmaceuticals Co Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
7%

Over the last year, the Operating Income growth was -8%. The average annual Operating Income growth rates for Chengdu Easton Biopharmaceuticals Co Ltd have been 3% over the past three years , 7% over the past five years .

Back to Top